Pharmacokinetics of Escalating Doses of Intravenous Repinotan in Healthy Male Volunteers

@article{Heinig2005PharmacokineticsOE,
  title={Pharmacokinetics of Escalating Doses of Intravenous Repinotan in Healthy Male Volunteers},
  author={Roland Heinig and M B{\"o}ttcher},
  journal={Clinical Drug Investigation},
  year={2005},
  volume={25},
  pages={115-123}
}
AbstractObjective: To investigate the pharmacokinetics of intravenous (IV) repinotan, a potent selective full serotonin (5-HT1a) receptor agonist, after administration of escalating doses/infusion rates to healthy volunteers with extensive or poor metaboliser phenotype, and to compare weight-adjusted (mg/kg) to fixed (mg/ day) dosing regimens. Subjects and methods: The pharmacokinetic profile of IV repinotan was evaluated in healthy male volunteers. In eight studies, extensive metabolisers… 
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Effects of a Targeted Exposure of Intravenous Repinotan in Patients With Acute Ischemic Stroke: Modified Randomized Exposure Controlled Trial (mRECT)
TLDR
The mRECT demonstrated the feasibility of conducting a rigorous trial using a short therapeutic window demanding clinical and radiographic criteria to optimize patient selection and a Point-of-Care test to achieve a targeted exposure to repinotan.
A Randomized , Double-Blind , Placebo-Controlled Trial to Evaluate the Efficacy , Safety , Tolerability , and Pharmacokinetic / Pharmacodynamic Effects of a Targeted Exposure of Intravenous Repinotan in Patients With Acute Ischemic Stroke Modified
Background and Purpose—Repinotan hydrochloride is a serotonin (5-HT)1A receptor full agonist with evidence of neuroprotection in animal models of permanent and transient focal ischemia. The purpose
"A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/ pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke"
mRECT demonstrated the feasibility of conducting a rigorous trial using a short therapeutic window demanding clinical and radiographic criteria to optimize patient selection and a Point-of-Care test

References

SHOWING 1-8 OF 8 REFERENCES
Polymorphic Drug Oxidation
TLDR
The high incidence of PM (and of heterozygous extensive metabolisers) of S-mephenytoin in Asia might be the reason for the reported higher sensitivity of Orientals to diazepam compared with Caucasians.
The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects.
TLDR
The therapeutic implications for each of the classes of drugs affected by this genetic polymorphism in drug metabolism are discussed and it is emphasized that it is difficult to attain therapeutic plasma concentrations for some drugs in high activity extensive metabolizers.
Neuroprotection is unlikely to be effective in humans using current trial designs: an opposing view.
TLDR
To summarize recent neuroprotective trials, there has been no useful balance of benefit over risk, and the message is accurate: the drugs or doses the authors tried were inadequate.
Toward Wisdom From Failure: Lessons From Neuroprotective Stroke Trials and New Therapeutic Directions
TLDR
Key challenges and complexities in translational stroke research are reviewed by focusing on the “disconnect” in the way that neuroprotective agents have traditionally been assessed in clinical trials compared with animal models and new concepts in ischemic pathophysiology are explored.
Recommendations for Clinical Trial Evaluation of Acute Stroke Therapies
TLDR
The recommendations contained in this document may help to focus attention on how to achieve the goal of developing an expanding number of a effective and safe acute stroke therapies.